12月2日晚间，普莱柯（603566）生物工程股份有限公司(以下简称"普莱柯")公告称，公司拟认购中信 农业科技股份有限公司(以下简称"中信农业")持有的中普生物制药有限公司(以下简称"中普生物")4.04% 股权。 公告显示，中普生物由普莱柯、中牧实业股份有限公司(以下简称"中牧股份（600195）")和中信农业于 2018年6月共同出资成立，经营范围主要为口蹄疫疫苗业务；截至目前，普莱柯持股比例为46.97%，中 牧股份持股比例为48.99%，中信农业持股比例为4.04%。 中国商业经济学会副会长宋向清对《证券日报》记者表示，对普莱柯而言，拿下中普生物控制权可完善 其在畜牧疫病疫苗领域的布局，形成更完整的产品矩阵与业务协同。尤其是在畜牧业规模化发展的背景 下，口蹄疫作为畜禽重大疫病，其疫苗市场需求稳定，此次收购能为普莱柯锁定该领域的核心资产，符 合其长期发展规划。 公告显示，中普生物2024年以及今年上半年实现净利润分别亏损2620.74万元和1823.7万元。 对于上市公司收购亏损的参股公司股权现象，上海与梅管理咨询合伙企业合伙人沈萌接受《证券日报》 记者采访时表示，标的企业的经营表现无法满足财务投资者 ...

Core Insights - Dabeinong's stock increased by 1.67% on November 11, with a trading volume of 575 million yuan [1] - The company reported a net profit growth of 92.56% year-on-year for the first nine months of 2025 [2] Financing and Trading Activity - On November 11, Dabeinong had a financing buy-in of 82.04 million yuan and a net financing buy of 3.39 million yuan, with a total financing balance of 943 million yuan [1] - The financing balance represents 5.07% of the circulating market value and is above the 80th percentile of the past year [1] - Dabeinong's short selling activity included a repayment of 17,200 shares and a sale of 83,900 shares, with a short selling balance of 13.06 million yuan, also above the 90th percentile of the past year [1] Company Overview - Dabeinong was established on October 18, 1994, and listed on April 9, 2010, focusing on feed production, sales, and crop seed cultivation [1] - The company's revenue composition includes 63.42% from feed products, 25.08% from pig farming products, and smaller contributions from other agricultural products [1] Shareholder and Institutional Holdings - As of September 30, 2025, Dabeinong had 227,400 shareholders, a decrease of 5.84% from the previous period [2] - The top institutional shareholder is Guotai CSI Livestock Breeding ETF, holding 76.99 million shares, an increase of 27.76 million shares [2] - Hong Kong Central Clearing Limited is the fifth-largest shareholder, with 51.63 million shares, an increase of 14.93 million shares [2]

Core Insights - Multiple A-share companies reported significant profit growth in their Q3 earnings, indicating a positive trend in the market. Group 1: Company Performance - Jiangshan Co., Ltd. reported a Q3 revenue of 1.157 billion yuan, a year-on-year increase of 2.75%, with a net profit of 86.73 million yuan, up 11,890.01% [1][2] - Yongmaotai's Q3 revenue reached 1.655 billion yuan, a 59.65% increase year-on-year, with a net profit of 30.41 million yuan, up 6,319.92% [1][2] - Nanjing Public Utilities achieved Q3 revenue of 3.102 billion yuan, a 165.53% increase year-on-year, with a net profit of 84.62 million yuan, up 2,492.12% [3][4] - Daheng Technology reported Q3 revenue of 453 million yuan, a 26.86% increase year-on-year, with a net profit of 71.48 million yuan, up 1,960.72% [1][5] - Gaode Infrared's Q3 revenue was 1.134 billion yuan, a 71.07% increase year-on-year, with a net profit of 401 million yuan, up 1,143.72% [1][6] Group 2: Factors Driving Growth - Jiangshan's profit surge was attributed to increased sales volume, reduced costs, and investment gains from stock sales [1] - Yongmaotai's profit growth was driven by substantial revenue increase and improved operational efficiency in its automotive parts business [1][2] - Nanjing Public Utilities' significant profit increase was due to the delivery of larger real estate projects compared to the previous year [3][4] - Daheng Technology's growth was linked to improved performance in machine vision and digital broadcasting systems, along with gains from financial assets [1][5] - Gaode Infrared's revenue boost was due to the resumption of delayed project deliveries and expansion into consumer markets [1][6]

Core Viewpoint - Zhejiang Securities acts as an independent financial advisor for the major asset sale of Green Kang Biochemical Co., Ltd, responding to inquiries from the Shenzhen Stock Exchange regarding the transaction's details and implications [1]. Group 1: Transaction Overview - Green Kang Biochemical plans to sell 100% equity of three subsidiaries, including Green Kang (Yushan) Film Materials Co., Ltd, Green Kang (Haining) Film Materials Co., Ltd, and Green Kang New Energy (Shanghai) Import and Export Trade Co., Ltd, to Jiangxi Raoxin New Energy Materials Co., Ltd for a cash price of 0 yuan [1]. - As of December 31, 2024, the total book value of the three subsidiaries is -100.05 million yuan, with an assessed value of -18.74 million yuan, resulting in an appreciation rate of 81.27% [1]. Group 2: Financial Analysis - The subsidiaries are experiencing negative gross margins due to changes in supply and demand in the photovoltaic industry, leading to indications of long-term asset impairment [2]. - Revenue forecasts for Green Kang Yushan were adjusted from an original projection of 276.93 million yuan in 2025 to 819.99 million yuan due to declining product prices and insufficient financial support [2]. - The assessment method for Green Kang Haining and Green Kang New Energy was based solely on the asset-based approach due to their operational status, aligning with industry practices [2]. Group 3: Historical Context - In January 2023, Green Kang Biochemical acquired 100% equity of Green Kang Yushan amid a booming photovoltaic industry, establishing a dual business model of veterinary products and photovoltaic film products [3]. - Subsequent capital increases of 70 million yuan in June 2023 and 150 million yuan in December 2024 were aimed at supporting operational needs and improving financial conditions [3]. - The verification by Zhejiang Securities supports the rationality and compliance of the major asset sale, safeguarding the interests of the listed company and minority shareholders [3].

Investment Rating - The report maintains a "Cautious Recommendation" rating for the company [4][7]. Core Insights - The company's revenue for 2024 reached 1.335 billion yuan, a year-on-year increase of 106.0%, with a net profit attributable to shareholders of 189 million yuan, up 14.3% year-on-year [1]. - The copper foil business is identified as the core driver of revenue growth, with significant contributions from the electrolytic copper foil segment, which saw a revenue increase of 1477.1% in 2024 [2]. - The company has successfully developed high-value-added high-end copper foil products, including high-temperature extended copper foil and low-profile copper foil, which are expected to drive future growth [4]. Revenue Breakdown - In 2024, the revenue breakdown is as follows: - Electrolytic copper foil: 683 million yuan, accounting for 51.2% of total revenue - Electric and steam: 304 million yuan, 22.8% of total revenue - Veterinary medicine products: 292 million yuan, 21.9% of total revenue - Pesticide products: 21 million yuan, 1.6% of total revenue [2]. Profitability and Cost Management - The company has effectively managed costs, with a sales expense ratio of 1.65% and a management expense ratio of 5.77% in 2024, both showing a decrease compared to the previous year [3]. - The gross margin for the electrolytic copper foil business was -5.35% in 2024, but it is expected to recover in the future as industry processing fees stabilize [3]. Future Outlook - The company is focusing on "import substitution and high-end iteration" in its copper foil business, with plans to expand production capacity based on market demand [4]. - Future profit projections estimate net profits of 279 million yuan in 2025, 356 million yuan in 2026, and 446 million yuan in 2027, with corresponding PE ratios of 31, 24, and 19 [4][6].